Improving the Patient-Provider Experience in Agitation Treatment
|
Activity Overview
Discover how one hospital’s experience using sublingual dexmedetomidine built patient-provider trust and helped patients in the de-escalation pathway during the treatment of acute agitation in schizophrenia and bipolar I or II disorder. This case study will provide an example of how sublingual dexmedetomidine is a quick and effective non-invasive treatment option that allows for rapid assessment of calmer patients without the risk of excessive sedation.
More in this Series:
Engaging the Experts Podcast: Putting the Patient First: Updates in the Management of Acute Agitation
On-Demand Webinar: New Approaches to Managing Acute Agitation in the Hospital Setting
Target Audience
This activity is for pharmacists who practice in hospitals and health systems who care for or are interested in the care of patients with acute agitation.
At the conclusion of this activity, participants should be able to:
- Review acute agitation guidelines.
- Characterize my institution’s acute agitation management pathway.
- Work with stakeholders to develop a new acute management pathway.
- Collaborate with interprofessional teams to identify the potential for nonpharmacologic and pharmacologic treatments for acute agitation.
- Advocate for appropriate acute agitation treatment in clinical settings.
Faculty
Koth Cassavaugh, PharmD, Activity Chair
Director of Pharmacy
Auburn Community Hospital
Auburn, New York
len Gard CPhT-Adv, CSPT is the national director of compounding compliance for Option Care Health and is a member of the State of Illinois Board of Pharmacy. Mr. Gard is an inaugural member of the PTCB’s CSPT exam development committee. He is an active member of ASHP having served as the chair of the Pharmacy Technician Forum Executive Committee and is a current member of the Education and Workforce Development Committee. Additionally, Mr. Gard has been an active member of NHIA and was recently appointed as Co-Chair of the Sterile Compounding Practice Committee.
Relevant Financial Relationship Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
- The following persons in control of this activity’s content have relevant financial relationships:
- Koth M. Cassavaugh – BioXcel: Speaker’s Bureau
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity. All other persons in control of content do not have any relevant financial relationships with an ineligible company.
Methods and CE Requirements
This activity consists of a reading. There is no CE associated with this activity.
Provided by ASHP
Supported by an unrestricted educational grant from BioXcel